---
title: The Sequencing Buyer's Guide 
---

Our Sequencing Buyer's Guide is finally here! Access your copy here to discover how next-generation sequencing is rapidly evolving

| View in browser Dear , Next-generation sequencing (NGS) has evolved rapidly over the last decade, and as a result, has revolutionised genomic research. In particular, the COVID-19 pandemic propelled genomics and DNA sequencing into the spotlight. Therefore, the latest edition of our Sequencing Buyer’s Guide, which is available to download for free, could not be more relevant right now. Download the 2022 Sequencing Buyer's Guide Here We would like to give a special thank you to our contributors for their help and guidance in compiling this report : Adam Ameur, Associate Professor, SciLifeLabNational Genomics Infrastructure, Uppsala University Andrew Beggs, Academic & Scientific Lead for Genomics, Birmingham Health Partners Darren Griffin, Professor of Genetics, University of Kent David Baker, Head of Sequencing, Quadram Institute David Smith, Professor Emeritus, Mayo Clinic Eddy de Boer, Researcher and PhD Student, University Medical Center Groningen Floriana Manodoro, Higher Scientific Officer, Institute of Cancer Research Leah Catchpole, Genomics Pipeline Team Leader, Earlham Institute Luciano Martelotto, Head of the Single Cell and Spatial Omics Laboratory, Australian Center for Epigenetics, South Australian ImmunoGenomics Cancer Centre Luis Zapata Ortiz, Institute of Cancer Research Fellow, Institute of Cancer Research Miten Jain, Assistant Research Scientist, University of California, Santa Cruz Natalie Thorne, Innovation and Technology Lead, Melbourne Genomics Health Alliance Paola Niola, Senior Applications Specialist, UCL Genomics Shawn Baker, Genomics Start-up Advisor/Investor/Consultant, SanDiegOmics Tamas Korcsmaros, Senior Lecturer, Imperial College London Tara Paton, Service Manager for Genotyping, Sanger and Next Generation Sequencing, The Centre for Applied Genomics Tatiana Borodina, NGS Unit Team Leader, Max Delbrück Center for Molecular Medicine Tiffany Boughtwood, Managing Director, Australian Genomics William Scott, Wellcome Trust Clinical Research Career Development Fellow and Honorary Consultant in Endocrinology and Diabetes, Imperial College London Download the 2022 Sequencing Buyer's Guide Here Report contents: Chapter 1: Preparing for NGS Chapter 2: What sequencing technologies are available? Chapter 3: How to choose the right sequencing technology Chapter 4: Could Out-Sourcing NGS be a better option? Chapter 5: Single-Cell and spatial sequencing­ Chapter 6: Innovation in the sequencing space Chapter 7: Dealing with NGS data Chapter 8: Making NGS accessible Chapter 9: ESG in Genomics Chapter 10: Planning for shifts in the NGS market Chapter 11: What does the future of NGS hold?   We are convinced that this new, intelligence-driven format will provide you with unrivalled insights into various aspects of the NGS space. Find out for yourself by downloading the Sequencing Buyer’s Guide here   Best regards, Diana Georgi Content and Conference Producer Front Line Genomics Limited E: diana@frontlinegenomics.com T: +44 020 8191 8810 W: www.frontlinegenomics.com Front Line Genomics Limited is registered in England and Wales. Company Number 10421716, VAT: GB 297 742 548. Registered Office: Ground Floor, Cromwell House, 15 Andover Road, Winchester, SO23 7BT, UK Front Line Genomics Copyright © 2021, All rights reserved. You are receiving this email because we believe you have a legitimate interest in its content. If you're not interested in NGS content but would like to receive emails about other webinar and report topics, please let us know by clicking here. Alternatively, if you do not wish to receive emails about our reports, please adjust your email preferences or unsubscribe by clicking here. |
| --- |